Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123613 · ClinicalTrials.gov registry record · Phase 2
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
A Phase 2 study, sponsored by DiaMedica Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT04123613: Completed Phase 2 study, sponsored by DiaMedica Therapeutics.
NCT04123613 is a Phase 2 study that has completed, run by DiaMedica Therapeutics. The registered enrollment target is 79 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04123613, a Phase 2 study, has completed, sponsored by DiaMedica Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
Primary Outcome
Incidence, severity, and causality of adverse events
Interventions
- DRUG DM199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
What the finished NCT04123613 record still lists
NCT04123613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 1 intervention - of which DM199 is the first listed.
NCT04123613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04123613 about?
NCT04123613 is a clinical study titled "Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)". An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
What is the current status of trial NCT04123613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2019-12-17. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT04123613?
The interventions under investigation include: DM199 (DRUG).
Who is sponsoring clinical trial NCT04123613?
This trial is sponsored by DiaMedica Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04123613's enrollment target sits among peer trials
79 884th of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI